measure. The granularity of the comorbidities was insufficient, as many registers coded, for example, diabetes mellitus without any extra information.

### Registry

<table>
<thead>
<tr>
<th>ATTRA</th>
<th>BIOBADASER</th>
<th>BSRBR-RA</th>
<th>RABBIT</th>
<th>SCOMMAND</th>
</tr>
</thead>
<tbody>
<tr>
<td>Country</td>
<td>Spain</td>
<td>Spain</td>
<td>Spain</td>
<td>Spain</td>
</tr>
<tr>
<td>Number of Participants</td>
<td>2334</td>
<td>3012</td>
<td>5217</td>
<td>13652</td>
</tr>
<tr>
<td>Germany</td>
<td>10281</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Gender

- **Female**: 1808 (77%)
- **Male**: 526 (23%)

### Age at observation start date

- **Female**: 59 (52.66)
- **Male**: 58 (47.63)

### First observation start date

- **Female**: Feb-2002, Oct-1999
- **Male**: Oct-2001, Aug-2006

Conclusion: This is the first analysis of data from the newly mapped OMOP CDM across five European registers. Through mapping the registers into a CDM, and using the same script, the ability to undertake collaborative analysis without sharing patient level data outside of the country can be realised. Due to differences in study design and data capture, there needs to be a focus on harmonising the coding and analysing of the comorbidities and drugs across registries.

Disclosure of Interests: Liane Keansley-Fleet: None declared, Kimmy Hycht: None declared, Martin Schaefer: None declared, Doreen Huschek: None declared, Anja Strangfeld: None declared, Jakub Zavada Speakers bureau: Abbvie, Eli-Lilly, UCB, Sanofi, Consultant of: Abbvie, UCB, Sanofi, Gilead, Markita Lodovig: None declared, Delphine Courvoisier Speakers bureau: Medtriks Switzerland, Christoph Tellenbach: None declared, Kim Lauper Speakers bureau: Medtriks Switzerland, Carlos Sánchez-Piedra: None declared, Nuria Montero: None declared, Jesús-Tomás Sánchez-Costa: None declared, Daniel Prieto-Alhambra Consultant of: Amgen (speaker fees and advisory board membership fees paid to DPA's department) and UCB (consultancy fees paid to DPE department), Grant/research support from: grants and other from AMGEN, grants, non-financial support and other from UCB BioPharma, grants from Les Laboratoires Servier, outside the submitted work, Edward Burn: None declared

DOI: 10.1136/annrheumdis-2021-eular.3974

### Bone & Joints

#### OP0106

**THE ASSOCIATIONS BETWEEN BARIATRIC SURGERY AND HIP OR KNEE ARTHROPLASTY, AND HIP OR KNEE OSTEOARTHRITIS: A COHORT STUDY FROM SWEDISH NATIONWIDE HEALTHCARE REGISTRIES**

T. Burkard1, D. Holmberg2, T. Hugle3, A. M. Burden1,4, 1ETH Zurich, Department of Chemistry and Applied Biosciences, Zurich, Switzerland; 2Karolinska University Hospital, Department of Molecular medicine and Surgery, Stockholm, Sweden; 3Lausanne University Hospital (CHUV) and University Lausanne, Department of Rheumatology, Lausanne, Switzerland; 4Maastricht University Medical Center+, Department of Clinical Pharmacy and Toxicology, Maastricht, Netherlands

**Background:** Osteoarthritis (OA) is a slowly developing chronic joint disease mainly characterized by joint pain which may lead to physical disability. OA in weight bearing joints, such as the hip and knee, was suggested to be susceptible to high body weight. In end-stage disease, hip and knee OA are often treated with arthroplasty. The impact of weight loss among obese patients on hip and knee arthroplasty has not been assessed.

**Objectives:** To assess the association between bariatric surgery and hip or knee arthroplasty. As a secondary aim, we assessed the association between bariatric surgery and hip or knee OA in a secondary care setting.

**Methods:** We performed a propensity score (PS)-matched cohort study using data from Swedish nationwide healthcare registries (patient registry [secondary care], causes of death registry, prescribed drug registry). Patients aged 18-79 years who underwent bariatric surgery between 2006 and 2019 were matched to up to 2 obese bariatric surgery free patients (called unexposed patients) based on their PS. PS-matching was carried out in risk set sampling to reduce selection bias, within 4 sequential cohort entry blocks. In a 6 month follow-up period, patients were followed in an “as-treated” approach until the outcome or censoring due to onset of an exclusion criterion, change of exposure status, or end of study follow-up period. We applied Cox proportional hazard regression to calculate hazard ratios (HR) with 95% confidence intervals (CI) of hip or knee arthroplasty, and separately of hip or knee OA, among bariatric surgery patients when compared to obese unexposed patients. Additionally, we performed analyses in subgroups of age, sex, joint location, bariatric surgery type, and by duration of follow-up.

**Results:** A total of 39 392 bariatric surgery patients were PS-matched to 61 085 obese unexposed patients. The secondary endpoint of hip OA among mean age of 42 years, a mean follow-up of 6.5 years, and 72.5% of patients were women. We observed 1138 and 1108 hip or knee arthroplasties among bariatric surgery and obese unexposed patients, respectively. We observed an overall increased risk of hip or knee arthroplasty among bariatric surgery patients (HR of 1.43, 95% CI 1.32-1.55), compared to obese unexposed patients. The risk for hip arthroplasty was higher than that for hip arthroplasty among bariatric surgery patients (HR of 1.36, 95% CI 1.24-1.76, and HR of 1.21, 95% CI 1.06-1.39, respectively). Patients who underwent combined absorbive and restrictive bariatric surgery yielded highest risks of hip or knee arthroplasty (HR of 3.58, 95% CI 1.34-9.54). Risks of hip or knee arthroplasty decreased with duration of follow-up (highest risks 1-3 years post-bariatric surgery, HR of 1.79, 95% CI 1.56-2.07). In secondary analyses, risks of secondary care knee OA were decreased among bariatric surgery versus obese unexposed patients (HR of 0.84, 95% CI 0.79-0.90). We observed lower risks for knee OA (HR of 0.82, 95% CI 0.76-0.88) than for hip OA (HR of 0.90, 95% CI 0.79-1.01) and observed lowest risks of hip or knee OA in early follow-up (1-3 years post-bariatric surgery) with a HR of 0.79, 95% CI 0.71-0.88, stable thereafter at a HR of 0.87, 95% CI 0.78-0.97.

**Conclusion:** Our results suggest that substantial weight loss among obese patients is associated with decreased risks of secondary care hip and knee OA. Increased risks of hip and knee arthroplasty after bariatric surgery are likely the result of increased operability of patients who have lost a substantial amount of excess body weight. Stronger associations for the knee than for the hip in both arthroplasty and OA are consistent with existing literature suggesting a stronger impact of body weight on knee than on hip joints.

**Acknowledgements:** We thank Prof. Dr. Jesper Lagergren (Karolinska Institutet, Stockholm, Sweden) for hosting Dr. Theresa Burkard for a research stay at the Upper Gastrointestinal Surgery Group and making the data available for use. Furthermore, we thank Dr. Giola Santoni (Karolinska Institutet, Stockholm, Sweden) for her technical support.

**Disclosure of Interests:** Theresa Burkard: None declared, Dag Holmberg: None declared, Thomas Hugle Consultant of: Pfizer, Abbvie, Novartis, Grant/research support from: GSK, Jansen, Pfizer, Abbvie, Novartis, Roche, MSD, Sanofi, BMS, Eli Lilly, UCB, Andrea Michelle Burden: None declared

DOI: 10.1136/annrheumdis-2021-eular.3974

#### OP0107

**CLINICAL EFFICACY OF ROMOSOZUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS FOR 12 MONTHS**

Y. Kanawaya1, R. Sugimoto2, Toyota Kosei Hospital, Orthopedic surgery and Rheumatology, Toyota, Japan; 2Toyota Kosei Hospital, Orthopedic surgery and Rheumatology, Toyota, Japan

**Background:** Romosozumab (ROMO), a monoclonal antibody that binds sclerostin, increases bone formation and decreases bone resorption. And although it is a novel therapeutic agent for osteoporosis, which has shown high effects of increasing bone density and inhibiting fragile fracture in overseas clinical trials. However the clinical efficacy for rheumatoid arthritis complicated with osteoporosis (RA-OP) is unknown.

**Objectives:** To evaluate the clinical efficacy of ROMO in patients with RA-OP for 12 months.

**Methods:** RA patients diagnosed according to the 2010 ACR/EULAR criteria. All patients met at least one of the following criteria were eligible; a bone mineral density T score of -2.5 or less at the lumbar spine or total hip and either one or more moderate or severe vertebral fractures or two or more mild vertebral fractures. All patients were initiated ROMO from between March and December, 2019. The total number of patients was 13 cases. The ROMO dose was 210mg at once every 4 weeks. In all cases native or activated vitamin D has been used. We reviewed the results for 12 months about the increase and decrease of bone mineral density (BMD) of lumbar spine (LS) and total hip (TH) byDEXA and bone turnover markers, intact n-terminal propeptide type I procollagen(PINP) and tartrate-resistant acid phosphatase form 5b(TRACP-5b).

**Results:** Our results suggest that substantial weight loss among obese patients is associated with decreased risks of secondary care hip and knee OA. Increased risks of hip and knee arthroplasty after bariatric surgery are likely the result of increased operability of patients who have lost a substantial amount of excess body weight. Stronger associations for the knee than for the hip in both arthroplasty and OA are consistent with existing literature suggesting a stronger impact of body weight on knee than on hip joints.

**Acknowledgements:** We thank Prof. Dr. Jesper Lagergren (Karolinska Institutet, Stockholm, Sweden) for hosting Dr. Theresa Burkard for a research stay at the Upper Gastrointestinal Surgery Group and making the data available for use. Furthermore, we thank Dr. Giola Santoni (Karolinska Institutet, Stockholm, Sweden) for her technical support.

**Disclosure of Interests:** Theresa Burkard: None declared, Dag Holmberg: None declared, Thomas Hugle Consultant of: Pfizer, Abbvie, Novartis, Grant/research support from: GSK, Jansen, Pfizer, Abbvie, Novartis, Roche, MSD, Sanofi, BMS, Eli Lilly, UCB, Andrea Michelle Burden: None declared

DOI: 10.1136/annrheumdis-2021-eular.3974